Patent ID: 11918643
Assignee: CUREVAC SE
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 1:
2. A composition comprising
(a) an mRNA comprising:
(i) at least one coding sequence encoding a SARS-CoV-2 spike protein (S) at least 95% identical to SEQ ID NO: 10 and is a pre-fusion stabilized spike protein (S_stab) comprising K986P and V987P stabilizing mutations and T19R, F157del, R158del, L452R, T478K, D614G, P681R and D950N amino acid substitutions relative to SEQ ID NO: 10, and
(ii) at least one heterologous untranslated region (UTR); and
(b) at least one pharmaceutically acceptable carrier,
wherein the mRNA is complexed or associated with a lipid nanoparticle (LNP) and wherein the LNP comprises:
(i) at least one cationic lipid;
(ii) at least one neutral lipid;
(iii) at least one steroid or steroid analogue; and
(iv) at least one PEG-lipid,
wherein (i) to (iv) are in a molar ratio of about 20-60% of the at least one cationic lipid, 5-25% of the at least one neutral lipid, 25-55% of the at least one steroid or steroid analogue, and 0.5-15% of the at least one PEG-lipid.